​

BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

BridgeBio Pharma Revenue Highlights

Latest Revenue (Y)

$362.37M

Latest Revenue (Q)

$180.60M

Main Segment (Y)

Product

Main Geography (Y)

License

BridgeBio Pharma Revenue by Period

BridgeBio Pharma Revenue by Year

DateRevenueChange
2025-12-31$362.37M63.30%
2024-12-31$221.90M2285.27%
2023-12-31$9.30M-88.02%
2022-12-31$77.65M11.38%
2021-12-31$69.72M745.14%
2020-12-31$8.25M-79.66%
2019-12-31$40.56M100.00%
2018-12-31-100.00%
2017-12-31--

BridgeBio Pharma generated $362.37M in revenue during NA 2025, up 63.30% compared to the previous quarter, and up 4392.87% compared to the same period a year ago.

BridgeBio Pharma Revenue by Quarter

DateRevenueChange
2026-03-31$180.60M17.13%
2025-12-31$154.18M27.74%
2025-09-30$120.70M9.17%
2025-06-30$110.56M-5.20%
2025-03-31$116.63M1882.88%
2024-12-31$5.88M115.30%
2024-09-30$2.73M26.01%
2024-06-30$2.17M-98.97%
2024-03-31$211.12M11998.57%
2023-12-31$1.75M-57.35%
2023-09-30$4.09M149.30%
2023-06-30$1.64M-10.13%
2023-03-31$1.83M-2.35%
2022-12-31$1.87M453.25%
2022-09-30$338.00K-99.54%
2022-06-30$73.75M4253.36%
2022-03-31$1.69M-86.85%
2021-12-31$12.89M449.74%
2021-09-30$2.34M-95.66%
2021-06-30$54.02M11593.51%
2021-03-31$462.00K278.69%
2020-12-31$122.00K-98.50%
2020-09-30$8.13M100.00%
2020-06-30-100.00%
2020-03-31--100.00%
2019-12-31$13.82M-48.32%
2019-09-30$26.74M100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

BridgeBio Pharma generated $180.60M in revenue during Q1 2026, up 17.13% compared to the previous quarter, and up 3070.32% compared to the same period a year ago.

BridgeBio Pharma Revenue Breakdown

BridgeBio Pharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 21Dec 20Dec 19
License and Service$128.32M---
Royalty$11.39M---
Product$362.37M$3.79M--
License-$65.92M$8.00M$13.80M

BridgeBio Pharma's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (72.17%), License and Service (25.56%), and Royalty (2.27%).

Quarterly Revenue by Product

Product/ServiceMar 26Dec 25Sep 25Jun 25Mar 25Mar 23Sep 22Jun 22Mar 22Sep 21Jun 21Sep 20
Royalty$9.50M$7.11M$4.28M---------
Product$180.60M$254.26M$108.11M--$1.46M$759.00K$987.00K----
License and Service$4.42M$120.01M$8.31M$1.83M$338.00K$73.75M------
Net Product Revenue---$71.50M$36.74M-------
Royalty Revenue---$1.62M--------
License--------$235.00K$1.58M$8.00M-

BridgeBio Pharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Product (92.84%), Royalty (4.88%), and License and Service (2.27%).

BridgeBio Pharma Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 19
License$13.80M

BridgeBio Pharma's latest annual revenue breakdown by geography, as of Dec 19: License (100.00%).

Quarterly Revenue by Country

CountryMar 23Sep 22Jun 22Mar 22Sep 21Jun 21Sep 20
License and Service$1.83M$338.00K$73.75M----
Product---$1.46M$759.00K$987.00K-
License---$235.00K$1.58M$8.00M-

BridgeBio Pharma's latest quarterly revenue breakdown by geography, as of Mar 23: License and Service (100.00%).

BridgeBio Pharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JAZZJazz Pharmaceuticals$4.27B$1.07B
BMRNBioMarin Pharmaceutical$3.22B$766.21M
EXELExelixis$2.32B$610.81M
MRNAModerna$1.94B$389.00M
IONSIonis Pharmaceuticals$944.00M$246.09M
BBIOBridgeBio Pharma$362.37M$180.60M
ASNDAscendis Pharma$266.72M$95.89M
RNAAtrium Therapeutics$18.75M$12.47M
ROIVRoivant Sciences$8.26M$2.00M
RVMDRevolution Medicines--
SMMTSummit Therapeutics--

BBIO Revenue FAQ

What is BridgeBio Pharma’s yearly revenue?

BridgeBio Pharma's yearly revenue for 2025 was $362.37M, representing an increase of 63.30% compared to 2024. The company's yearly revenue for 2024 was $221.9M, representing an increase of 2285.27% compared to 2023. BBIO's yearly revenue for 2023 was $9.3M, representing a decrease of -88.02% compared to 2022.

What is BridgeBio Pharma’s quarterly revenue?

BridgeBio Pharma's quarterly revenue for Q1 2026 was $180.6M, a 17.13% increase from the previous quarter (Q4 2025), and a 54.84% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $154.18M, a 27.74% increase from the previous quarter (Q3 2025), and a 2521.22% increase year-over-year (Q4 2024). BBIO's quarterly revenue for Q3 2025 was $120.7M, a 9.17% increase from the previous quarter (Q2 2025), and a 4318.01% increase year-over-year (Q3 2024).

What is BridgeBio Pharma’s revenue growth rate?

BridgeBio Pharma's revenue growth rate for the last 3 years (2023-2025) was 3795.17%, and for the last 5 years (2021-2025) was 419.78%.

What are BridgeBio Pharma’s revenue streams?

BridgeBio Pharma's revenue streams in c 25 are License and Service, Royalty, and Product. License and Service generated $128.32M in revenue, accounting 25.56% of the company's total revenue Royalty generated $11.39M in revenue, accounting 2.27% of the company's total revenue Product generated $362.37M in revenue, accounting 72.17% of the company's total revenue, up 9453.60% year-over-year.

What is BridgeBio Pharma’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of BridgeBio Pharma was Product. This segment made a revenue of $362.37M, representing 72.17% of the company's total revenue.